A US electronic health record study found that adults with obesity who started semaglutide or tirzepatide had lower recorded hazards of anxiety and depression than matched patients using naltrexone-bupropion. However, among adults without type 2 diabetes, tirzepatide was linked to higher recorded hazards of anxiety and insomnia than semaglutide, underscoring the need for cautious monitoring.